Population pharmacokinetics of rosuvastatin in pediatric patients with heterozygous familial hypercholesterolemia

详细信息    查看全文

• 作者：Merran Macpherson ; Bengt Hamrén…
• 关键词：Rosuvastatin ; Population pharmacokinetics ; Pediatric ; Children ; Familial hypercholesterolemia
• 刊名：European Journal of Clinical Pharmacology
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：72
• 期：1
• 页码：19-27
• 全文大小：1,293 KB
• 参考文献：1.Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ (2010) Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 105:69–76PubMed CrossRef
  2.Tzeng TB, Schneck DW, Birmingham BK, Mitchell PD, Zhang H, Martin PD, Kung LP (2008) Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. Curr Med Res Opin 24:2575–2585PubMed CrossRef
  3.Igel M, Sudhop T, von Bergmann K (2002) Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol 42:835–845PubMed CrossRef
  4.Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz E (2003) Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 25:2822–2835PubMed CrossRef
  5.Luvai A, Mbagaya W, Hall AS, Barth JH (2012) Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol 6:17–33PubMed PubMedCentral
  6.AstraZeneca. CRESTOR SmPC http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​Referrals_​document/​Crestor_​29/​WC500010495.​pdf . Accessed 15 March 2014
  7.Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ (2002) No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 42:1116–1121PubMed CrossRef
  8.Avis HJ, Hutten BA, Gagne C, Langslet G, McCrindle BW, Wiegman A, Hsia J, Kastelein JJ, Stein EA (2010) Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 55:1121–1126PubMed CrossRef
  9.Langslet G, Braamskamp MJ, McCrindle B, Cassiman D, Francis G, Gagne C, Gaudet D, Morrison KM, Wiegman A, Turner T, Miller E, Raichlen J, Martin PG, Stein E, Kastelein J (2014) Effect of rosuvastatin therapy on arterial wall changes in children and adolescents with familial hypercholesterolemia: results from the CHARON study. J Am Coll Cardiol 63(Suppl 1):A1379
  10.AstraZeneca. Crestor (Rosuvastatin calcium) tablets. http://​www.​fda.​gov/​downloads/​Drugs/​DevelopmentAppro​valProcess/​Develop%20​mentResources/​UCM205895.​pdf . Accessed 5 February 2015
  11.Hull CK, Penman AD, Smith CK, Martin PD (2002) Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 772:219–228PubMed CrossRef
  12.Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ. NONMEM 7.2.0 users guides. Ellicott City, Maryland, USA: Icon Development Solutions; 1989–2011. Introduction to NONMEM 7.2.0. https://​nonmem.​iconplc.​com/​nonmem7/​Release_​Notes_​Plus/​nm720.​pdf . Accessed 20 August 2015
  13.West GB, Brown JH, Enquist BJ (1997) A general model for the origin of allometric scaling laws in biology. Science 276:122–126PubMed CrossRef
  14.Anderson BJ, van Lingen RA, Hansen TG, Lin YC, Holford NH (2002) Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. Anesthesiology 96:1336–1345PubMed CrossRef
  15.Van Kesteren C, Mathot RA, Raymond E, Armand JP, Dittrich C, Dumez H, Roche H, Droz JP, Punt C, Ravic M, Wanders J, Beijnen JH, Fumoleau P, Schellens JH (2002) Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. J Clin Oncol 20:4065–4073PubMed CrossRef
  16.European Medicines Agency Committee for Medicinal Products in Human Use. Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​Scientific_​guideline/​2009/​09/​WC500003066.​pdf . Accessed 5 February 2015
  17.Edginton AN, Shah B, Sevestre M, Momper JD (2013) The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years. Clin Pharmacokinet 52:693–703PubMed CrossRef
  
• 作者单位：Merran Macpherson (1)
  Bengt Hamrén (3)
  Marjet J. A. M. Braamskamp (4) (5)
  John J. P. Kastelein (4) (5)
  Torbjörn Lundström (3)
  Paul D. Martin (2)
  
  1. Wright Dose Ltd, Fifth Floor, Charter House, 2 Woodlands Road, Altrincham, Cheshire, UK
  3. AstraZeneca, Mölndal, Sweden
  4. Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
  5. Department of Pediatrics, Academic Medical Center, Amsterdam, The Netherlands
  2. AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Pharmacology and Toxicology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1041

文摘

Purpose Data from two clinical studies (hyperCholesterolaemia in cHildren and Adolescents taking Rosuvastatin OpeN label [CHARON; NCT01078675] and Study 4522IL/0086) were used to describe rosuvastatin pharmacokinetics in patients with heterozygous familial hypercholesterolemia aged ≥6 to <18 years.